Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efpegerglucagon in Congenital Hyperinsulinism
NCT04732416Phase 2Active, not recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2022
- Primary completion
- Jun 2026
- Modality
- Peptides
- Countries
- 5
01
Overview
A Phase 2 trial of efpegerglucagon in congenital hyperinsulinism (HI), sponsored by Hanmi Pharmaceutical. Started May 2022; status: active, not recruiting.
02
Drugs
efpegerglucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT04732416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732416.